deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT00691184

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis

Sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

Conditions Onychomycosis/Onycholysis and Tinea Pedis
Interventions Placebo Terbinafine Terbinafine Hydrochloride
Updated 1 time since 2024 Last updated: Jun 3, 2008 Started: Feb 28, 2005 Primary completion: Jun 30, 2005 Completion: Dec 31, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00691184, this PHASE1 trial focuses on Onychomycosis/Onycholysis and Tinea Pedis and remains completed. Sponsored by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.), it has been updated 1 time since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

1 version recorded
Completed — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Data source: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations